Skip to main content

Advertisement

SpringerLink
Log in

High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Golgi phosphoprotein 3 (GOLPH3) is recently demonstrated to function as an oncogene involved in the development and progression of cancers. However, little is known about GOLPH3 expression and its clinical significance in hepatocellular carcinoma (HCC). The levels of GOLPH3 messenger RNA (mRNA) and protein in HCC cell lines and fresh tissues were determined by quantitative RT-PCR and western blotting. Additionally, the protein expression of GOLPH3 was detected in 167 paraffin-embedded HCC samples by immunohistochemistry. GOLPH3 mRNA and protein was overexpressed in HCC cell lines and tissues than the immortalized normal hepatocyte cell line LO2 and the adjacent nontumorous live tissues, respectively. High GOLPH3 expression was positively correlated with high serum AFP level (P = 0.015) and more tumor recurrence or metastasis (P = 0.010). In addition, HCC patients with high GOLPH3 expression had poorer overall survival (hazard ratio (HR), 1.87; 95 % confidence interval (CI), 1.19–2.94; P = 0.006) and poorer disease-free survival (HR, 1.90; 95 % CI, 1.21–2.98; P = 0.005) than those with low GOLPH3 expression. The cumulative 5-year survival rate was only 35.19 % (95 % CI, 26.18–44.20 %) in the high GOLPH3 expression group, whereas it was 55.93 % (95 % CI, 43.26–68.60 %) in the low GOLPH3 expression group. Furthermore, multivariate Cox regression analysis demonstrated that the expression of GOLPH3, tumor size, and tumor multiplicity were independent prognostic predictors for HCC patients. GOLPH3 was overexpressed in HCC at both the mRNA and protein levels, and high expression of GOLPH3 could be served as a novel and potential prognostic biomarker for HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124–34.

    Article  CAS  PubMed  Google Scholar 

  3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94:153–6.

    Article  CAS  PubMed  Google Scholar 

  4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  6. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225–35.

    Article  PubMed  Google Scholar 

  7. Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009;249:118–23.

    Article  PubMed  Google Scholar 

  8. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252–7.

    Article  CAS  PubMed  Google Scholar 

  9. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524–32.

    Article  CAS  PubMed  Google Scholar 

  10. Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.

    Article  CAS  PubMed  Google Scholar 

  11. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Wu CC, Taylor RS, Lane DR, Ladinsky MS, Weisz JA, Howell KF. GMx33: a novel family of trans-Golgi proteins identified by proteomics. Traffic. 2000;1:963–75.

    CAS  PubMed  Google Scholar 

  13. Dippold HC, Ng MM, Farber-Katz SE, et al. GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell. 2009;139:337–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Abraham RT. GOLPH3 links the Golgi network to mTOR signaling and human cancer. Pigment Cell Melanoma Res. 2009;22:378–9.

    Article  PubMed  Google Scholar 

  15. Scott KL, Kabbarah O, Liang MC, et al. GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer. Nature. 2009;459:1085–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Scott KL, Chin L. Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res. 2010;16:2229–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep. 2011;26:1337–42.

    CAS  PubMed  Google Scholar 

  18. Li XY, Liu W, Chen SF, Zhang LQ, Li XG, Wang LX. Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study. J Neurooncol. 2011;105:159–63.

    Article  CAS  PubMed  Google Scholar 

  19. Zeng ZL, Lin HX, Zhao XH, et al. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res. 2012;18:4059–69.

    Article  CAS  PubMed  Google Scholar 

  20. Li H, Guo L, Chen SW, et al. GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med. 2012;10:168.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Hua X, Yu L, Pan W, et al. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol. 2012;7:127.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Wang JH, Chen XT, Wen ZS, et al. High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One. 2012;7:e45622.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hu BS, Hu H, Zhu CY, Gu YL, Li JP. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol. 2013;34:515–20.

    Article  PubMed  Google Scholar 

  24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25:402–8.

    Article  CAS  PubMed  Google Scholar 

  25. Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol. 2002;161:207–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Dowen SE, Neutze DM, Pett MR, et al. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene. 2003;22:2531–40.

    Article  CAS  PubMed  Google Scholar 

  27. Gorringe KL, Boussioutas A, Bowtell DD. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Gene Chromosome Cancer. 2005;42:247–59.

    Article  CAS  Google Scholar 

  28. Wullschleger S, Loewith R, Hall MN. mTOR signaling in growth and metabolism. Cell. 2006;124:471–84.

    Article  CAS  PubMed  Google Scholar 

  29. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2007;6:729–34.

    Article  Google Scholar 

  30. Guertin DA, Sabatini DM. Defining the role of MTOR in cancer. Cancer Cell. 2007;12:9–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China and the Hunan Natural Science Foundation. The funders had no role in the study design, data collection, analysis, decision to publish, or the preparation of the manuscript.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gastroenterology, The First Affiliated Hospital, NanHua University, 69 ChuanShan Road, Hengyang, 421001, People’s Republic of China

    Guang-Sheng Hu, Wei Shi, Ai-Jun Liao, Yu-Hong Yao, Bin Zeng & Jie Yuan

  2. Department of Emergency, Guangzhou First People’s Hospital, Guangzhou Medical University, 1 Panfu Road, Guangzhou, 510180, People’s Republic of China

    Ying-Qing Li

  3. Department of Gastroenterology, Hunan Provincial People’s Hospital, 61 Liberation Road West, Changsha, 410005, People’s Republic of China

    Yu-Ming Yang

Authors
  1. Guang-Sheng Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying-Qing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-Ming Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ai-Jun Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu-Hong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bin Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jie Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Guang-Sheng Hu or Ying-Qing Li.

Additional information

Guang-Sheng Hu and Ying-Qing Li contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, GS., Li, YQ., Yang, YM. et al. High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma. Tumor Biol. 35, 8625–8632 (2014). https://doi.org/10.1007/s13277-014-2105-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2105-8

Keywords

Search

Navigation